Comparative studies on the potential use of Lu-based radiopharmaceuticals for the palliative therapy of bone metastases.

In recent years, radionuclides like Lu have been considered promising material for the creation of therapeutic radiopharmaceuticals. With the therapeutic use of radiopharmaceuticals, the absorbed doses per tumor may exceed 10 Gy. It is extremely important that doses absorbed by healthy organs and tissues do not exceed the threshold for the incidence of deterministic effects.